PepGen (NASDAQ:PEPG) Rating Lowered to “Sell” at Wall Street Zen

PepGen (NASDAQ:PEPG – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Sunday, Wall Street Zen reports.

Several other research firms also recently commented on PEPG. HC Wainwright reaffirmed a “buy” rating on shares of PepGen in a research report on Wednesday, September 9th. Guggenheim lifted their price target on PepGen from $7.00 to $15.00 and gave the stock a “buy” rating in a report on Friday. Wedbush boosted their price target on PepGen from $4.00 to $10.00 and gave the company an “outperform” rating in a research note on Wednesday, November 11th. Weiss Ratings raised PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 22nd. Finally, Bank of America upgraded PepGen from an “underperform” rating to a “neutral” rating and increased their price objective for the stock from $2.50 to $6.00 in a research report on Tuesday, November 10th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, PepGen has a consensus rating of “Moderate Buy” and a consensus target price of $11.40.

Read Our Latest Research Report on PepGen

PepGen Stock Performance

Shares of PEPG stock opened at $4.19 on Friday. The company has a market capitalization of $290.20 million, a price-to-earnings ratio of -3.92 and a beta of 2.02. The company has a 50-day simple moving average of $2.82 and a 200 day simple moving average of $2.96. PepGen has a 52 week low of $1.31 and a 52 week high of $7.80.

PepGen (NASDAQ:PEPG – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.01). Sell-side analysts forecast that PepGen will post -1.13 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Commodore Capital LP boosted its stake in shares of PepGen by 31.6% in the first quarter. Commodore Capital LP now owns 4,475,000 shares of the company’s stock valued at $7,921,000 after buying an additional 1,075,000 shares during the period. ADAR1 Capital Management LLC acquired a new stake in PepGen during the second quarter worth approximately $4,664,000. Marshall Wace LLP increased its stake in PepGen by 136.3% during the 3rd quarter. Marshall Wace LLP now owns 2,049,112 shares of the company’s stock worth $4,959,000 after acquiring an additional 1,182,120 shares during the period. AWM Investment Company Inc. increased its stake in PepGen by 201.1% during the 3rd quarter. AWM Investment Company Inc. now owns 1,806,419 shares of the company’s stock worth $4,372,000 after acquiring an additional 1,206,419 shares during the period. Finally, BlackRock Inc. bought a new position in PepGen during the 2nd quarter worth $2,348,000. Institutional investors and hedge funds own 58.01% of the company’s stock.

About PepGen

(Get Free Report)

PepGen is a clinical-stage biotechnology company developing oligonucleotide medicines for people with neuromuscular diseases. Its Enhanced Delivery Oligonucleotide (EDO) platform is designed to help deliver these medicines to muscle tissue. The company’s pipeline includes PGN-EDO51, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping, and PGN-EDODM1, an investigational candidate for myotonic dystrophy type 1.

Further Reading

Analyst Recommendations for PepGen (NASDAQ:PEPG)

Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.